Independent, up-to-date news and information for multiple myeloma patients and their families.
Home
News
Opinion
Forum
Resources
Links
Blogs
Events
About Us
Forums
Forums Home
Register
•
Login
Advanced Search
Search query
Search for keywords:
Advanced Search Tips
Search for all terms or use query as entered
Search for any terms
Search for author:
Use * as a wildcard for partial matches.
Search options
Search in forums:
Select the forum or forums you wish to search in. Subforums are searched automatically if you do not disable “search subforums“ below.
Welcome
Welcome & Tips for Getting Started
Member Introductions / Personal Stories
Multiple Myeloma Discussion
Multiple Myeloma
Treatments & Side Effects
Weekly Polls
Insurance & Patient Assistance Programs
Support Groups & Events
To Those We Will Always Remember
General Discussion
The Burgundy Café
Web Site Support
FAQ
Troubleshooting
Comments and Suggestions
Search subforums:
Yes
No
Search within:
Post subjects and message text
Message text only
Topic titles only
First post of topics only
Display results as:
Posts
Topics
Sort results by:
Author
Post time
Forum
Topic title
Post subject
Ascending
Descending
Limit results to previous:
All results
1 day
7 days
2 weeks
1 month
3 months
6 months
1 year
Return first:
All available
0
25
50
100
200
300
400
500
600
700
800
900
1000
characters of posts
The Beacon is brought to you in part by:
Recent Activity
Comments
Forum Posts
Eb
: With respect to Mark’s comments about allos, I am not familiar with the observation that 30-40 percent of...
Art
: Mark I have to once again concur with Terry. I am sorry if I was not specific but this was also a bad...
Susan Morse
: Another excellent column,Lou. I can emphasize with your frustration with the FDA and getting this drug...
Lori Puente
: Thank you Sean. I loved all of what you wrote, your viewpoint, your hopes.
Pat Killingsworth
: Thanks so much, Linda! But I expect things to be difficult. I like to share the smallest of...
Dan D
: Ignore the last post....
Dan D
: Not only are HB readings soft and bounce around, but I have read they should NOT necessarily be the sole basis for treat...
Tj
: Hi, I was first diagnosed with mb waldenstrøms 19 years ago, but last year I got this IgM MGUS diagnos. Might have been ...
Art
: I posted other because it depends on my Hemoglobin reading at each test. I bounce around a bit and I can go either way. ...
Nancy S
: My MM is 'inactive' now....
Click here for more activity.
News
Popular
Recent
A New Beacon For The Multiple Myeloma Community
Suspended Resveratrol Clinical Trial: More Details Emerge
Revlimid Maintenance Therapy Is Effective For Multiple Myeloma After Stem Cell Transplant (ASCO 2010)
Multiple Myeloma, Smoldering Multiple Myeloma, And MGUS May Be Linked To Osteoporosis
Blood Cancers Forum Focuses On Importance Of Clinical Trials
Perifosine Combination May Be Effective In Relapsed/Refractory Multiple Myeloma (ASH 2011)
Beacon NewsFlashes – February 6, 2012
Siltuximab May Be Effective In Certain Patients With Advanced Multiple Myeloma (ASH 2011)
Experts Publish Consensus Statement On Maintenance Therapy In Multiple Myeloma
Celgene Updates Timeline For Pomalidomide Approval In The U.S. And Europe
Resources
Popular
Recent
Red Wine, Resveratrol, And Multiple Myeloma: The Evidence Is Promising, But Needs Further Study
Curcumin And Multiple Myeloma: Preclinical And Early Clinical Studies Are Promising; Still Awaiting More Clinical Evidence
Pomalidomide (CC-4047, Actimid)
Revlimid
The H1N1 Swine Flu Vaccine And Multiple Myeloma: A Comprehensive Review
Baylor Charles A. Sammons Cancer Center at Dallas
John Theurer Cancer Center
The University of Kansas Hospital
SNS01-T
IPH 2101 (anti-KIR)
Links
Popular
Recent
Nick’s Myeloma Blog
UK Myeloma Forum
MMRF – What Is Multiple Myeloma?
Wikipedia – Multiple myeloma
Leukemia & Lymphoma Society (LLS) – Myeloma
Jeanie Living With Multiple Myeloma
Multiple Myeloma Missive
Jeremy’s Multiple Myeloma Journey
Keep In Touch
Joe’s Gathering
Subscribe
Get Beacon News by Email
Get Forum posts by Email
Subscribe to our News RSS feed
Subscribe to our Forum RSS feed
Become our fan on Facebook!
Follow us on Twitter!
Follow us on Google+
News Archives
▼
2012
(16)
▼
February
(4)
Perifosine Combination May Be Effective In Relapsed/Refractory Multiple Myeloma (ASH 2011)
Beacon NewsFlashes – February 6, 2012
Siltuximab May Be Effective In Certain Patients With Advanced Multiple Myeloma (ASH 2011)
Experts Publish Consensus Statement On Maintenance Therapy In Multiple Myeloma
►
January
(12)
Celgene Updates Timeline For Pomalidomide Approval In The U.S. And Europe
Questions And Answers About The FDA’s Approval Of Subcutaneous Velcade
Beacon BreakingNews – Subcutaneous Velcade Receives FDA Approval
Marizomib May Be Effective In Relapsed / Refractory Multiple Myeloma (ASH 2011)
The Top Myeloma Beacon Resource Articles Of 2011
BT-062 Shows Activity In Patients With Advanced Myeloma (ASH 2011)
Panobinostat Combination May Be Effective In Relapsed And Velcade-Refractory Multiple Myeloma (ASH 2011)
Smoldering Myeloma: What Do The Latest Research Findings Mean? A Discussion With Dr. Ola Landgren
Beacon NewsFlashes - January 12, 2012
Revlimid-Dexamethasone Combination Delays Disease Progression In Patients With Smoldering Multiple Myeloma (ASH 2011)
The Top Myeloma Beacon News Articles Of 2011
Zolinza Tallies Mixed Results In Relapsed And Refractory Multiple Myeloma Patients (ASH 2011)
►
2011
(176)
►
December
(17)
Pomalidomide Continues To Show Promise As Treatment For Relapsed Multiple Myeloma (ASH 2011)
ASH 2011 – The Meeting’s Myeloma-Related “Hidden Gem”
ASH 2011 – Initial Thoughts On The Meeting's Key Myeloma-Related Findings
ASH 2011 Multiple Myeloma Update – Day Four
ASH 2011 Multiple Myeloma Update – Day Three Afternoon: Other New Therapies
ASH 2011 Multiple Myeloma Update – Day Three Afternoon: Carfilzomib And Pomalidomide
MLN9708, "Son of Velcade," Shows Promising Initial Results In Multiple Myeloma (ASH 2011)
Elotuzumab Combination Effective For Relapsed And Refractory Multiple Myeloma (ASH 2011)
ASH 2011 Multiple Myeloma Update – Day Three Morning: Current Therapies
ASH 2011 Multiple Myeloma Update – Day Three Morning: New Therapies
ASH 2011 Multiple Myeloma Update – Day Two
Beacon Breaking News - Carfilzomib To Get Standard, Not Priority, FDA Review
ASH 2011 Multiple Myeloma Update – Day One
Spanish Experts Ask: What Is The Path To A Cure For Myeloma?
The Myeloma Beacon To Provide Comprehensive Coverage Of The 2011 American Society Of Hematology Meeting (ASH 2011)
Initial Treatment With Cyclophosphamide, Velcade, And Dexamethasone Compares Favorably In Terms Of Response Rates And Side Effects
Czech Researchers Look At Impact Of Chromosomal Abnormalities In Newly Diagnosed Multiple Myeloma
►
November
(11)
Beacon NewsFlashes - November 30, 2011
Beacon Breaking News - FDA Accepts Carfilzomib New Drug Application
Genetic Differences Linked To Increased Risk Of Multiple Myeloma
Canadian Study Takes In-Depth Look At Second Stem Cell Transplants As Salvage Therapy
High Sclerostin Levels Linked To Advanced Disease And Poor Bone Formation In Multiple Myeloma Patients
Disease Stability Affects Transplant Outcomes In Myeloma Patients Unresponsive To Initial Treatment
Lower-Dose Thalidomide Compares Well To Higher-Dose Option In Treatment Of Advanced Myeloma Patients
New Review Looks At Treatment Strategies For Relapsed And Refractory Multiple Myeloma Patients – Part 2: Treatment Strategies At Relapse
New Review Looks At Treatment Strategies For Relapsed And Refractory Multiple Myeloma – Part 1: Retreatment With Novel Agents
Extramedullary Myeloma
Thalidomide Maintenance Therapy Fails To Provide Consistent Overall Survival Benefit
►
October
(11)
Study Finds Early And Delayed Stem Cell Transplants Have Comparable Efficacy In Newly Diagnosed Multiple Myeloma Patients
Thalidomide-Based Therapy Yields Mixed Outcomes In Multiple Myeloma Patients With A Deletion In Chromosome 17
Beacon NewsFlashes - October 26, 2011
Experts Review Current And Future Research Into New Multiple Myeloma Treatments
Myeloma Patients Relapsing After Pomalidomide Therapy May Benefit From Certain Salvage Therapies
Treanda In Combination With Steroids May Be Effective In Relapsed And Refractory Multiple Myeloma Patients
Neupogen And Neulasta Show Comparable Activity In Multiple Myeloma Patients After Stem Cell Transplantation
Myeloma Beacon Introduces New Service For Tracking Postings At Myeloma-Related Blogs
NCCN Modifies Guidelines For Multiple Myeloma A Second Time In 2011
Addition Of Doxil To Velcade Improves Treatment Outcomes For Multiple Myeloma Patients
Istodax-Velcade-Dexamethasone Combination May Be Effective In Relapsed/Refractory Myeloma
►
September
(16)
Laser Surgery May Be An Effective Alternative For The Treatment Of Jawbone Death
High Level Of Stem Cells In The Blood May Be Associated With Favorable Prognosis For Myeloma Patients
Beacon BreakingNews - Onyx Submits Carfilzomib For FDA Approval
Beacon NewsFlashes – September 26, 2011
Recent Advances In The Treatment Of Myeloma Bone Disease
European Regulators Conclude Revlimid Safety Review, Say Drug's Benefit-Risk Balance Remains Positive
Results Of PET/CT Scans May Predict Survival In Multiple Myeloma Patients
Researchers Find High Rates Of Sexual Dysfunction After Stem Cell Transplantation
Multiple Myeloma Experts Recommend Tailored Therapies For Elderly Myeloma Patients
Sequential Treatment Using Velcade And Thalidomide Is Effective In High-Risk Multiple Myeloma Patients
Guidelines For The Management Of Side Effects In Older Myeloma Patients – Part 4: Novel Agent Use In Specific Patient Populations
Stem Cell Transplantation As Salvage Therapy Is Most Effective In Myeloma Patients With Previous Long Remission
Guidelines For The Management Of Side Effects In Older Myeloma Patients – Part 3: Revlimid-Related Side Effects
Myeloma Beacon Launches Sponsorship Program And Patient Advisory Board
Beacon NewsFlashes – September 5, 2011
Subcutaneous Velcade: Information For Multiple Myeloma Patients
►
August
(18)
Researchers Determine Outcomes For Myeloma Patients Who Have Failed To Respond To Novel Agent Therapies
Beacon NewsFlashes – August 30, 2011
Guidelines For The Management Of Side Effects In Older Myeloma Patients – Part 2: Thalidomide-Related Side Effects
“Mini” Donor Stem Cell Transplant As Second Transplant May Improve Outcomes In Myeloma
Guidelines For The Management Of Side Effects In Older Myeloma Patients – Part 1: Velcade-Related Side Effects
Beacon NewsFlashes – August 24, 2011
Study Suggests MGUS Patients Receive Inadequate Evaluation, Follow-Up, And Treatment
Revlimid Maintenance Therapy After Donor Stem Cell Transplantation Is Not Recommended For Multiple Myeloma Patients
Stem Cell Transplants May Be Feasible In Elderly Multiple Myeloma Patients
Beacon NewsFlashes - August 15, 2011
Treating Multiple Myeloma Patients: Optimizing Response While Minimizing Side Effects
Gene Therapy Advance In Leukemia Suggests New Treatment Options For Multiple Myeloma
Multiple Myeloma And MGUS Patients May Have An Increased Risk Of Developing Certain Cancers
Addition Of Cyclophosphamide To Revlimid And Dexamethasone May Improve Responses In Newly Diagnosed Myeloma Patients
Beacon NewsFlashes – August 8, 2011
The Role Of Autologous Stem Cell Transplantation In Multiple Myeloma
Residual Disease Before Stem Cell Transplantation May Predict Survival In Multiple Myeloma Patients
Beacon NewsFlashes – August 1, 2011
►
July
(12)
Percentage Of Cancerous Plasma Cells Post Transplant May Predict Outcome In Myeloma Patients
Cyclophosphamide-Thalidomide-Dexamethasone Improves Response But Not Survival In Elderly Myeloma Patients
Beacon NewsFlashes – July 25, 2011
New Response Type May Help Determine Multiple Myeloma Patients’ Prognoses
Melphalan-Prednisone-Thalidomide Combination May Increase Survival In Elderly Multiple Myeloma Patients
Donor Stem Cell Transplantation May Benefit High-Risk Myeloma Patients
Fatigue And Multiple Myeloma: Study Highlights Role Of Mood, Reevaluates Role Of Pain
Velcade-Dexamethasone Maintenance Therapy Appears To Be Effective In Myeloma Patients Who Respond To Velcade Rescue Therapy
Obesity's Impact On Myeloma Stem Cell Transplant Outcomes: Not What You Probably Expected
Steroid-Free Three-Drug Combination Treatment May Be Effective In Multiple Myeloma
Beacon NewsFlashes - July 4, 2011
Stem Cell Collection Is Feasible After Short-Course Revlimid For Myeloma Patients
►
June
(17)
Early Relapse May Be Linked To Shorter Survival In Elderly Myeloma Patients
Experts Provide Guidelines To Help Myeloma Patients Prevent Infections (IMW 2011)
Velcade-Thalidomide-Dexamethasone May Be A Highly Effective Consolidation Therapy For Myeloma (EHA 2011)
Beacon NewsFlashes – June 20, 2011
Residual Disease And Chromosomal Abnormalities May Predict Early Myeloma Relapse (EHA 2011)
Transplantation Versus Novel Agents For Myeloma: Study Supports Transplantation (EHA 2011)
Myeloma Research To Be Presented At EHA Congress
Elotuzumab Combination Is Effective For Relapsed Myeloma (ASCO 2011)
Investigational Drug LY2127399 Shows Potential For Myeloma (ASCO 2011)
ASCO 2011 Multiple Myeloma Update – Day Four
ASCO 2011 Multiple Myeloma Update – Day Three, Part Two
Lorvotuzumab Mertansine Combination Shows Activity In Myeloma (ASCO 2011)
Myeloma Experts Present Additional Data On Revlimid And Secondary Cancers (ASCO 2011)
ASCO 2011 Multiple Myeloma Update - Day Three, Part One
ASCO 2011 Multiple Myeloma Update - Days One And Two
Study Suggests Longer Infusion Time Does Not Improve Safety Of Zometa For Myeloma Patients
Experts Draft Guidelines For The Prevention Of Blood Clots In Multiple Myeloma Patients (IMW 2011)
►
May
(16)
Complete Response After Stem Cell Transplant For Myeloma Indicates Best Prognosis
Certain Chromosomal Abnormalities May Negatively Affect Prognosis In Relapsed And Refractory Myeloma Patients Receiving Revlimid-Dexamethasone Therapy
Myeloma Research To Be Presented At The American Society of Clinical Oncology’s 47th Annual Meeting (ASCO 2011)
Experts Develop Guidelines For Treating Anemia In Multiple Myeloma Patients (IMW 2011)
The 2011 International Myeloma Workshop - Key Themes and Learnings
Beacon NewsFlashes – May 20, 2011
Velcade-Doxil-Dexamethasone-Thalidomide Combination May Be Effective In Relapsed/Refractory Myeloma
Beacon NewsFlashes – May 16, 2011
Experts Recommend Intravenous Bisphosphonates For Multiple Myeloma Bone Disease (IMW 2011)
IMW 2011 Multiple Myeloma Update – Day 4
IMW 2011 Multiple Myeloma Update – Day Three Part 2
IMW 2011 Multiple Myeloma Update – Day Three Part 1
Beacon BreakingNews – Updated Data On Revlimid Maintenance And Second Cancers Presented At IMW
IMW 2011 Multiple Myeloma Update – Day Two
IMW 2011 Multiple Myeloma Update – Day One
Beacon NewsFlashes – May 2, 2011
►
April
(15)
Researchers Identify Factors That May Put Multiple Myeloma Patients At Higher Risk For Osteonecrosis Of The Jaw
Thalidomide Receives New Safety Warning In Europe And Korea
More Studies Are Needed On Medications To Prevent Blood Clots In Multiple Myeloma Patients
Beacon NewsFlashes – April 25, 2011
Studies Aim To Improve Transplantation Response Rates In Multiple Myeloma Patients
Myeloma Research To Be Presented At The 13th International Myeloma Workshop
Mitoxantrone And Melphalan Regimen Is Effective And Well Tolerated In Multiple Myeloma Patients
Promising New Drugs For Myeloma: Will The Future Come Soon Enough?
Questions & Answers About The FDA’s Investigation Into The Safety of Revlimid And Thalidomide
Vertebroplasty Relieves Pain For Multiple Myeloma Patients With Spinal Fractures
FDA Announces Investigation Into Revlimid, Thalidomide, And Secondary Cancers
Mozobil May Help Myeloma Patients Collect Enough Stem Cells For A Second Transplant
Researchers Identify Risk Factors For Infectious Complications In Myeloma Patients Treated With Thalidomide-Based Combination Therapies
Beacon NewsFlashes – April 4, 2011
Pomalidomide May Be Effective In Myeloma Patients Who Develop Extramedullary Disease
►
March
(14)
Aredia Does Not Prevent Disease Progression In Smoldering Myeloma Patients
Revlimid And Secondary Cancers: An Update
Beacon NewsFlashes - March 28, 2011
Beacon BreakingNews - European Multiple Myeloma Researchers Issue Statement on Revlimid and Secondary Cancers
Genome Sequencing Reveals Clues About The Underlying Causes Of Multiple Myeloma
NCCN Modifies Guidelines For Multiple Myeloma
New Advances In Myeloma Vaccines – Part 5: Participating In A Clinical Trial For A Novel Multiple Myeloma Vaccine
The Top Myeloma Research Of 2010
Beacon NewsFlashes - March 14, 2011
New Advances In Myeloma Vaccines – Part 4: Ongoing Research
Revlimid May Be Equally Effective In Thalidomide-Resistant and Thalidomide-Sensitive Multiple Myeloma Patients
Kyphoplasty Is More Effective Than Non-Surgical Care In Multiple Myeloma Patients With Spinal Fractures
New Advances In Myeloma Vaccines – Part 3: Completed Clinical Trials
Revlimid Dosing Will Continue In MM-015 Trial
►
February
(14)
Thought Leader Perspective: Dr. Kenneth Anderson On The Future Of Myeloma Treatment
First Day Of Stem Cell Collection For Myeloma Patients Predicts Likelihood Of Collecting Enough Stem Cells For Transplantation
New Advances In Myeloma Vaccines – Part 2: Types Of Potential Myeloma Therapeutic Vaccines
Thought Leader Perspective: Dr. Kenneth Anderson On Treating Multiple Myeloma
New Advances In Myeloma Vaccines – Part 1: Introduction
Variations In Nervous System Genes May Put Multiple Myeloma Patients At Higher Risk For Thalidomide-Related Neuropathy
Myeloma Working Group Postpones Statement On Revlimid’s Potential Link To Second Cancers
Beacon NewsFlashes – February 14, 2011
Prognosis For Multiple Myeloma Patients With Chromosomal Abnormality t(4;14) Remains Poor
Split May Be Emerging Regarding Long-Term Revlimid Use
Beacon NewsFlashes - February 7, 2011
Revlimid Dosing To Continue In CALGB Maintenance Trial
Revlimid Cancer Controversy Flares
Bone Marrow Examination Can Predict Progression Of Multiple Myeloma
►
January
(15)
Revlimid Maintenance And Secondary Cancers In Myeloma Patients: More Details Emerge
Thalidomide-Velcade Combination Without Steroids Is Effective For Newly Diagnosed Multiple Myeloma Patients
Chemotherapy Regimen Without High-Dose Dexamethasone Reduces Infections In Multiple Myeloma Patients
Beacon NewsFlashes – January 24, 2011
Novel Agents As Salvage Therapy After Stem Cell Transplantation Improve Survival In Multiple Myeloma Patients
Continued Revlimid-Dexamethasone Treatment May Improve Survival In Myeloma Patients Achieving A Partial Response
Targeted Irradiation And Stem Cell Transplantation Show Promise In Phase 1 Clinical Trial For Multiple Myeloma
The Majority Of Rare Myelomas Are Associated With Poorer Survival Than Common Myelomas
Beacon NewsFlashes – January 11, 2011
Revlimid And Pomalidomide Elicit High Response Rates In Multiple Myeloma Patients Who Relapsed After Thalidomide Or Revlimid (ASH 2010)
Torisel And Velcade Combination Shows Promise As Treatment For Relapsed/Refractory Multiple Myeloma (ASH 2010)
Beacon NewsFlashes - January 6, 2011
Experimental Drug PD 0332991 Shows Encouraging Phase 1 Trial Results In Relapsed/Refractory Multiple Myeloma Patients (ASH 2010)
Treanda Shows Promising Activity In Relapsed/Refractory Multiple Myeloma Patients (ASH 2010 Meeting)
Zolinza Shows Promise In Clinical Trials For The Treatment of Multiple Myeloma (ASH 2010)
►
2010
(200)
►
December
(20)
Weekly Velcade Maintenance Therapy After Velcade-Based Initial Therapy Improves Response Rates In Elderly, Newly Diagnosed Myeloma Patients (ASH 2010)
Carfilzomib Shows Promise In Both Newly Diagnosed and Relapsed/Refractory Multiple Myeloma Patients (ASH 2010)
Early Stem Cell Transplantation May Improve Survival In Newly Diagnosed Multiple Myeloma Patients (ASH 2010)
Elotuzumab Combinations Show Encouraging Results In Relapsed/Refractory Multiple Myeloma (ASH 2010)
Velcade Subcutaneous Injections Show Similar Activity But Fewer Side Effects Compared To IV Injections In Myeloma Patients (ASH 2010)
Beacon NewsFlashes – December 10, 2010
Studies Support Revlimid Maintenance Therapy For Multiple Myeloma Patients (ASH 2010)
ASH 2010 Multiple Myeloma Update – Day Four
ASH 2010 Multiple Myeloma Update – Day Three Afternoon And Evening
Zometa May Improve Survival In Myeloma Patients (ASH 2010)
ASH 2010 Multiple Myeloma Update – Day Three Morning
Pomalidomide Shows Promising Results For Multiple Myeloma Patients Resistant To Revlimid And Velcade (ASH 2010)
Donor Stem Cell Transplant Offers No Comparative Benefit As Second Transplant In Multiple Myeloma Patients (ASH 2010)
ASH 2010 Multiple Myeloma Update - Day Two
Carfilzomib Continues To Show Promising Results For Multiple Myeloma (ASH 2010)
ASH 2010 Multiple Myeloma Update – Day One
Risk-Adapted Therapy For Multiple Myeloma
The Myeloma Beacon To Provide Comprehensive Coverage Of The 2010 American Society Of Hematology Meeting
Latest Myeloma Research To Be Presented At The 52nd Meeting Of The American Society of Hematology (ASH 2010)
Beacon SiteUpdate – Physician Columns To Be Added To The Myeloma Beacon
►
November
(16)
GlaxoSmithKline Halts All Further Development Of Resveratrol Drug SRT501
Certain Chromosomal Abnormalities Negatively Impact The Outcome Of Revlimid-Dexamethasone Therapy In Relapsed And Refractory Multiple Myeloma Patients
Turkish Translations Of Myeloma Beacon Articles Now Available
Long-Term Follow-Up Results Indicate Double Transplantation Is Superior To Single Transplantation For Myeloma
Beacon NewsFlashes – November 22, 2010
Xgeva Receives FDA Approval For Bone Disease In Solid Tumors, But Not Multiple Myeloma
Beacon BreakingNews – Xgeva Receives FDA Approval For Bone Disease In Solid Tumors, But Not Multiple Myeloma
Beacon NewsFlashes – November 17, 2010
Velcade May Increase Bone Formation In Multiple Myeloma Patients
Beacon SiteUpdate – Myeloma Beacon Launches Opinion Section
Beacon NewsFlashes – November 10, 2010
Growth Factor May Not Be Required Following Stem Cell Transplantation In Multiple Myeloma Patients
Multiple Myeloma Vaccine Shows Promise In Phase 1 Clinical Trial
Experts Publish Treatment Recommendations For Multiple Myeloma Patients With Kidney Impairment
Researchers Identify Factors Associated With Improved Survival In Myeloma Patients After Surgery For Skeletal Complications
Detection Of Rapidly Dividing Plasma Cells May Lead To More Targeted Treatment For Multiple Myeloma Patients
►
October
(16)
Patients With Myeloma Precursor Disease MGUS May Have An Increased Risk Of Developing Blood Clots
Prolia May Delay The Onset Of Bone Complications More Effectively Than Zometa In Multiple Myeloma Patients
Velcade Maintenance Shows Little Improvement For Myeloma Patients Who Fail To Achieve Complete Response Post-Transplant
Beacon NewsFlashes – October 25, 2010
Lower Dose Of Aredia Is Equally Effective But Better Tolerated In Newly Diagnosed Multiple Myeloma Patients
Experts Assess Key Bone Proteins As Prognostic Tools For Multiple Myeloma And Myeloma-Related Bone Disease
Istodax Achieves Little Response In Refractory Multiple Myeloma
New FDA Warning About Bisphosphonates Does Not Apply To Multiple Myeloma
Personal Perspective: The Struggle Of Treating Multiple Myeloma In Turkey’s Centralized Health Care System
Itraconazole May Worsen Velcade-Induced Side Effects In Relapsed Multiple Myeloma Patients
ArthroCare Receives FDA Clearance For A New Device To Treat Spinal Fractures
Beacon NewsFlashes – October 8, 2010
Carfilzomib Application For FDA Approval Is Delayed
Caring For Someone With Multiple Myeloma – Part 3: The Toll Of Caregiving
Chinese Study Suggests That Velcade May Protect Against Blood Clots In Newly Diagnosed Multiple Myeloma Patients
Caring For Someone With Multiple Myeloma – Part 2: Practical Caregiving
►
September
(14)
Caring For Someone With Multiple Myeloma – Part 1: Introduction To Being A Caregiver
Once-Weekly Velcade Is Equally Effective But Better Tolerated In Elderly Multiple Myeloma Patients
Beacon NewsFlashes – September 27, 2010
Velcade-Doxorubicin-Dexamethasone Treatment Can Reverse Kidney Damage Associated With Multiple Myeloma
Study Finds It Is Better To Dose Velcade After Melphalan Prior To Stem Cell Transplantation
Addition Of Velcade To Revlimid-Dexamethasone May Yield Better Prognosis For Myeloma Patients With Certain Chromosomal Abnormalities
Personal Perspective: Survivor Overcomes Multiple Myeloma And Amyloidosis
Multiple Myeloma-Associated Amyloidosis – What Every Patient Should Know
Long-Term Study Shows Thalidomide Delays Disease Progression In Smoldering Multiple Myeloma But Causes Significant Side Effects
Experts Recommend Against Donor Stem Cell Transplantation For Multiple Myeloma Patients Until Safety And Efficacy Is Improved
Cyclophosphamide, Low-Dose Thalidomide, And Dexamethasone Combination Is Safe And Effective For Multiple Myeloma Patients
Complete Response With Velcade-Melphalan-Prednisone Is Associated With Improved Outcomes In Newly Diagnosed Multiple Myeloma Patients
Beacon NewsFlashes – September 3, 2010
Guide To Nutrition In Multiple Myeloma – Part 2: Supplements
►
August
(16)
Oral Busulfan Treatment May Be More Effective But Not As Safe As Melphalan Prior To Stem Cell Transplant In Multiple Myeloma Patients
NICE Recommends Thalidomide Over Velcade As First Line Treatment For Multiple Myeloma In The U.K.
Guide To Nutrition In Multiple Myeloma – Part 1: An Introduction
Velcade-Dexamethasone Therapy Improves Prognosis Of Multiple Myeloma Patients With The Chromosomal Abnormality t(4;14)
Personal Perspective: Tips For How Every Myeloma Patient Can Be Their Own Advocate
Etoposide Is Highly Effective For Stem Cell Mobilization In Multiple Myeloma Patients
Hycamtin-Cyclophosphamide-Melphalan May Be Effective And Safe For Multiple Myeloma Patients
MGUS And Smoldering Multiple Myeloma: Experts Identify Risk Factors For Disease Progression And Establish Monitoring Guidelines - Part 2: Smoldering Myeloma
Beacon NewsFlashes – August 18, 2010
MGUS And Smoldering Multiple Myeloma: Experts Identify Risk Factors For Disease Progression And Establish Monitoring Guidelines - Part 1: MGUS
Velcade May Not Be As Effective In Relapsed And Refractory Multiple Myeloma Patients With Duplications In Chromosome 1
Plitidepsin Is Not Very Effective For Multiple Myeloma But Merits Further Study In Combination With Other Treatments
Personal Perspective: Myeloma Patient Pays It Forward By Creating A Myeloma Support Group
Neurological Monitoring May Help Reduce Velcade-Induced Nerve Damage In Multiple Myeloma Patients
Combination Of Thalidomide And Cyclophosphamide May Negatively Impact Stem Cell Collection
New Four-Drug Combination May Be Effective And Safe In Newly Diagnosed Multiple Myeloma Patients
►
July
(15)
Double Stem Cell Transplant With Low-Dose And High-Dose Melphalan Is An Effective Treatment For Multiple Myeloma
Higher Quality Response To Revlimid-Dexamethasone Combination Yields Better Prognosis For Relapsed And Refractory Multiple Myeloma Patients
Single-Agent Carfilzomib Continues To Show Promise For Relapsed And Refractory Multiple Myeloma
Thalidomide-Interferon Maintenance Therapy Increases Progression-Free Survival Time In Elderly Multiple Myeloma Patients
Beacon NewsFlashes - July 23, 2010
Bristol-Myers Squibb Halts Development of Tanespimycin
Research Shows No Difference Between Early And Later Treatment For Smoldering Multiple Myeloma
Heparin, Warfarin, And Aspirin Are Equally Effective In Preventing Blood Clots In Myeloma Patients Receiving Thalidomide (EHA 2010)
Abnormal Plasma Cells In The Blood May Indicate Aggressive And Treatment-Resistant Multiple Myeloma (EHA 2010)
Beacon NewsFlashes – July 14, 2010
Chromosomal Abnormalities May Predict Response To Initial Velcade-Based Myeloma Therapy (EHA 2010)
Study Reveals Common Features Of Long-Term Surviving Multiple Myeloma Patients (EHA 2010)
Donor Stem Cell Transplant Is Not More Effective Than Existing Treatments For Multiple Myeloma (EHA 2010)
Long-Term Thalidomide Treatment Improves Progression-Free Survival Of Myeloma Patients, But Does Not Extend Survival (EHA 2010)
Beacon NewsFlashes - July 1, 2010
►
June
(27)
Multiple Myeloma Research Presented At 15th Annual European Hematology Association Meeting (EHA 2010)
Everolimus In Combination With Revlimid Shows Potential For Relapsed Multiple Myeloma (ASCO 2010)
Cyclophosphamide, Velcade, And Dexamethasone Combination Shows Promise For Newly Diagnosed Multiple Myeloma (ASCO 2010)
Guide To Clinical Trials For Multiple Myeloma Patients – Part 6: Phil’s Trial And Success
Panobinostat Combinations Show Therapeutic Benefit In Advanced Multiple Myeloma (ASCO 2010)
Zometa Increases Overall Survival And Slows Bone Disease In Multiple Myeloma Patients (ASCO 2010)
Beacon NewsFlashes – June 22, 2010
Elotuzumab Combinations Show Encouraging Results In Multiple Myeloma (ASCO 2010)
Guide To Clinical Trials For Multiple Myeloma Patients – Part 5: Don’s Trial And Success
Recent Advances In Treating Myeloma Bone Disease (ASCO 2010)
Addition Of Thalidomide To Standard Treatment For Elderly Multiple Myeloma Patients Increases Efficacy (ASCO 2010)
Treatment Of Myeloma With Novel Agents May Be As Effective As Stem Cell Transplantation – Part 2: Revlimid-Velcade-Dexamethasone (ASCO 2010)
Treatment Of Myeloma With Novel Agents May Be As Effective As Stem Cell Transplantation – Part 1: Melphalan-Prednisone-Revlimid (ASCO 2010)
Management Of Nerve Damage In Myeloma Patients (ASCO 2010)
Prevention Of Blood Clots In Myeloma Patients Is Important (ASCO 2010)
Carfilzomib May Benefit Relapsed And Refractory Multiple Myeloma Patients (ASCO 2010)
Reduced-Dose Velcade-Thalidomide-Dexamethasone Combination Shows Promise As Initial Therapy Prior To Stem Cell Transplantation (ASCO 2010)
Beacon NewsFlashes - June 11, 2010
Revlimid Maintenance Therapy Is Effective For Multiple Myeloma After Stem Cell Transplant (ASCO 2010)
ASCO 2010 Multiple Myeloma Update – Day Four
ASCO 2010 Multiple Myeloma Update – Day Three
Pomalidomide-Dexamethasone Combination Has Therapeutic Benefit For Heavily Pre-Treated Multiple Myeloma Patients (ASCO 2010)
ASCO 2010 Multiple Myeloma Update – Day Two
ASCO 2010 Multiple Myeloma Update - Day One
Carfilzomib-Revlimid-Dexamethasone Combination Is Well Tolerated As Longer-Term Multiple Myeloma Treatment (ASCO 2010)
Beacon NewsFlashes – June 4, 2010
German Translations Of Myeloma Beacon Articles Now Available
►
May
(13)
Myeloma Research To Be Presented At The American Society of Clinical Oncology’s 46th Annual Meeting (ASCO 2010)
Melphalan-Prednisone-Thalidomide Combination Shows Anti-Myeloma Effects But No Survival Benefit In Elderly Patients
Multiple Myeloma, Smoldering Multiple Myeloma, And MGUS May Be Linked To Osteoporosis
Guide To Clinical Trials For Multiple Myeloma Patients – Part 4: Selecting A Clinical Trial That Is Right For You
An Overview Of Myeloma Treatment Options In Europe – Part 4: Management Of Side Effects
Thalidomide-Dexamethasone Is Safe And Effective In Newly Diagnosed Myeloma Patients With Impaired Kidney Function
Beacon NewsFlashes – May 14, 2010
Guide To Clinical Trials For Multiple Myeloma Patients – Part 3: Myths And Facts About Clinical Trials
An Overview Of Myeloma Treatment Options In Europe – Part 3: Treatment Practices At Relapse
Suspended Resveratrol Clinical Trial: More Details Emerge
Zolinza-Velcade Combination May Be Effective In Relapsed/Refractory Myeloma
Resveratrol Trial In Multiple Myeloma Suspended Due To Safety Concerns
An Overview Of Myeloma Treatment Options In Europe – Part 2: First-Line Treatment Practices
►
April
(15)
An Overview Of Myeloma Treatment Options In Europe – Part 1: Drug Availability
Elafin May Be Good Indicator Of A Common Stem Cell Transplant Complication
Beacon NewsFlashes – April 26, 2010
Guide To Clinical Trials For Multiple Myeloma Patients – Part 2: Benefits And Risks Of Clinical Trials
Follow-Up Results Confirm Survival Benefit Of Velcade-Melphalan-Prednisone Therapy in Multiple Myeloma Patients
Revlimid-Melphalan-Prednisone-Thalidomide Combination Is Effective And Safe In Relapsed/Refractory Myeloma
Causes Of And Treatments For Multiple Myeloma Drug-Induced Nerve Damage
Guide To Clinical Trials For Multiple Myeloma Patients – Part 1: Learning About Clinical Trials
New Guidelines For Managing Side Effects Of Thalidomide As Front-Line Myeloma Treatment
Beacon NewsFlashes – April 12, 2010
Personal Perspective: Cancer Inspires Multiple Myeloma Patient And Wife To Help Other Cancer Patients
Velcade-Doxorubicin-Dexamethasone Combination Followed By Thalidomide-Dexamethasone Is Safe And Effective In Relapsed/Refractory Multiple Myeloma
Velcade-Thalidomide-Dexamethasone Therapy After Stem Cell Transplant Improves Response In Multiple Myeloma Patients
Beacon NewsFlashes - April 5, 2010
Continuous, Low-Dose Cyclophosphamide And Prednisone Regimen Is Safe And Effective Salvage Treatment For Multiple Myeloma
►
March
(16)
Study Shows Stable Multiple Myeloma Rates Over The Past 50 Years In Sweden
Short-Course Kepivance Reduces Mouth Ulcers After Stem Cell Transplant In Myeloma Patients
Beacon NewsFlashes - March 29, 2010
Non-Marrow Tumors Increase Among Myeloma Patients As Survival And Detection Methods Improve
Beacon NewsFlashes – March 23, 2010
Myeloma Beacon Launches New Myeloma Discussion Forums
Cyclophosphamide-Thalidomide-Dexamethasone Combination Is Promising As First Line Treatment For Myeloma Prior To Stem Cell Transplant
Velcade-Doxil-Dexamethasone Combination Is Effective And Safe In Elderly Myeloma Patients
Bone Lesions Detected By MRI Can Predict Progression Of Smoldering Myeloma
New Test Helps Predict More Specific Prognoses For Smoldering Myeloma Patients
Dose-Adjusted Revlimid-Dexamethasone Combination Is Safe And Effective In Multiple Myeloma Patients With Reduced Kidney Function
Regardless Of Prior Therapies, Velcade Is Superior Over Dexamethasone In Relapsed Multiple Myeloma Patients
Beacon NewsFlashes – March 9, 2010
Study Documents The Impact Of Age At Diagnosis On Myeloma Patient Survival
Genetic Risk Factors And Treatment History May Predict Response In Patients With Relapsed/Refractory Myeloma
International Effort Updates Results From Multiple Myeloma Stem Cell Transplant Trials
►
February
(15)
Thalidomide As Induction And Maintenance Therapy Improves Response Rates In Multiple Myeloma Patients
The Top Myeloma Research Of 2009
Achieving Very Good Partial Response Indicates A Good Prognosis For Multiple Myeloma Patients, Study Finds
Beacon NewsFlashes – February 18, 2010
Curcumin And Multiple Myeloma: Preclinical And Early Clinical Studies Are Promising; Still Awaiting More Clinical Evidence
Total Therapy Regimen May Be Highly Effective In Newly Diagnosed Myeloma Patients
Unresponsiveness To Revlimid Or Thalidomide Indicates Poor Response To Stem Cell Transplant, Study Finds
Revlimid Maintenance Therapy Is Added To Multiple Myeloma Treatment Guidelines
Revlimid-Cyclophosphamide-Prednisone Combination May Be Highly Effective For Refractory Multiple Myeloma Patients
Vertebroplasty Relieves Pain And Restores Mobility In Myeloma-Related Spinal Fractures, Study Finds
Bone Formation And Degradation Proteins May Predict Progression Of Multiple Myeloma And Myeloma-Related Bone Disease
Beacon NewsFlashes – February 5, 2010
Addition Of Defibrotide To Melphalan-Prednisone-Thalidomide Combination Produces Fewer Side Effects In Multiple Myeloma Patients
Velcade-Doxil-Dexamethasone Regimen Followed By Post-Transplant Revlimid May Be A Highly Effective Treatment For Newly Diagnosed Myeloma Patients
Personal Perspective: Former Football Star And Young Father “Dominates” Cancer With Optimism, Information, And Support
►
January
(17)
Beacon NewsFlashes – January 29, 2009
Post-Transplant Revlimid Therapy Increases Complete Response Rates In Multiple Myeloma Patients, Study Finds (ASH 2009)
Despite Side Effects, High-Dose Melphalan Remains The Most Effective Dosage In Preparation For Stem Cell Transplantation
Velcade Induction and Maintenance Combinations Are Highly Effective In Elderly Multiple Myeloma Patients, Study Finds (ASH 2009)
Beacon NewsFlashes - January 25, 2010
Thought Leader Perspective: Dr. Robert Kyle On Myeloma Treatments Requiring Further Study
Statins Reduce Acute Graft-Versus-Host Disease In Allogeneic Stem Cell Transplants, Study Finds
Study Compares Out-Of-Pocket Expenses For Myeloma Patients Treated With Velcade, Revlimid, Or Thalidomide (ASH 2009)
Beacon NewsFlashes – January 14, 2010
Thought Leader Perspective: Dr. Robert Kyle On Treating Multiple Myeloma
Celgene Plans To Seek Approval Of Revlimid As An Initial Treatment For Multiple Myeloma
M-CSF May Act As Powerful Prognostic Factor For Multiple Myeloma
Papayas, Papain and Multiple Myeloma: A Potential Adjunct Therapy That Requires Further Evaluation
FDA Approves Velcade’s Data Showing Survival Benefit In Newly Diagnosed Myeloma Patients
Revlimid May Be More Effective Than Thalidomide In Newly Diagnosed Multiple Myeloma
Elotuzumab In Combination With Revlimid And Dexamethasone Shows Encouraging Results In Multiple Myeloma (ASH 2009)
Multiple Myeloma Patients On Thalidomide At Risk For Infection Despite Preventative Medication (ASH 2009)
►
2009
(269)
►
December
(17)
Velcade-Thalidomide-Dexamethasone Treatment Is Promising For Newly Diagnosed Multiple Myeloma (ASH 2009)
Addition Of Thalidomide To Induction Therapy Increases Response Rates In Younger And Older Multiple Myeloma Patients (ASH 2009)
NPI-0052 Shows Promise In Relapsed/Refractory Multiple Myeloma (ASH 2009)
Novel Therapeutic Agents May Reduce Kidney Impairment In Newly Diagnosed Myeloma Patients (ASH 2009)
Preemptive Treatment Benefits High-Risk Smoldering Myeloma Patients, Study Finds (ASH 2009)
Revlimid Maintenance Therapy Significantly Extends Disease-Free Survival
Zolinza Combination Treatments Offer Benefit For Multiple Myeloma Patients (ASH 2009)
Perifosine Combination Therapy Is Promising For Relapsed And Refractory Multiple Myeloma (ASH 2009)
Revlimid May Set “New Standard” For Treating Newly Diagnosed Multiple Myeloma In Elderly Patients (ASH 2009)
Tanespimycin-Velcade Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
Survival Greater Than 10 Years In Multiple Myeloma Is Related To Longer Treatment Duration (ASH 2009)
Beacon NewsFlashes - December 8, 2009
Velcade-Dexamethasone Combination Regimen Increases Survival In Newly Diagnosed High Risk Myeloma Patients (ASH 2009)
Carfilzomib Is Effective For Multiple Myeloma – Part 2: Treatment Of Specific Patient Groups (ASH 2009)
Carfilzomib Is Effective For Multiple Myeloma – Part 1: As A Single Agent Or In A Combination Therapy (ASH 2009)
Beacon NewsFlashes - December 3, 2009
Velcade-Melphalan-Prednisone-Thalidomide (VMPT) Treatment Is Highly Active In Elderly Myeloma Patients (ASH 2009)
►
November
(15)
Velcade-Torisel Combination Proves Highly Effective In Multiple Myeloma Patients (ASH 2009)
Serum Albumin Levels Indicate Severity Of Multiple Myeloma
New Velcade Combination Therapy Effective For Newly Diagnosed Myeloma Patients (ASH 2009)
Treatment Trends For Multiple Myeloma – Part 3: Options For Elderly Multiple Myeloma Patients
Single-Agent Actimid And Combination Actimid-Dexamethasone Regimens Are Promising Treatments For Relapsed Myeloma (ASH 2009)
Beacon NewsFlashes – November 23, 2009
Torisel Achieves Little Response In Relapsed Multiple Myeloma Patients
Myeloma Research To Be Presented At The American Society of Hematology’s 51st Annual Meeting (ASH 2009)
Vitamin C Inhibits Anti-Myeloma Activity Of Velcade
Beacon NewsFlashes – November 13, 2009
Treatment Trends For Multiple Myeloma – Part 2: Allogeneic Stem Cell Transplants
The H1N1 Swine Flu Vaccine And Multiple Myeloma: A Comprehensive Review
Beacon NewsFlashes – November 6, 2009
Lawsuit Filed To Overturn Ban On Payment For Bone Marrow Donations
Treatment Trends For Multiple Myeloma – Part 1: Autologous Stem Cell Transplants
►
October
(19)
Beacon NewsFlashes – October 30, 2009
Velcade-Doxil-Dexamethasone Combination Treatment Is Highly Effective In Newly Diagnosed Multiple Myeloma Patients
Thalidomide Improves Outcome Of Double Stem Cell Transplants In Younger Myeloma Patients
Study Shows Higher Survival With Revlimid And Low-Dose Dexamethasone Than Revlimid And High-Dose Dexamethasone In Multiple Myeloma Patients
Retreatment With Velcade As A Treatment Option For Relapsed Myeloma Patients
Phase 2 Clinical Trial Offers Positive Results For A Steroid-Free Multiple Myeloma Treatment
Beacon NewsFlashes – October 23, 2009
Study Shows Benefits Of Vesselplasty In The Treatment Of Spinal Fractures
New Recommendations Issued On Stem Cell Collection And Treatment With Revlimid, Thalidomide, And Velcade
Multiple Myeloma Study Finds “Complete Response” Is Generally Correlated With Survival
Myeloma Patients Are At Increased Risk For Blood Clots, Particularly Patients Using Revlimid Or Thalidomide
Beacon NewFlashes - October 15, 2009
Onyx Pharmaceuticals To Acquire Proteolix, Developer Of Carfilzomib
New Directory Could Assist In Myeloma Treatment
Beacon NewsFlashes – October 8, 2009
Carfilzomib Is Highly Active In Relapsed Myeloma Patients
Immune System Cells Protect Myeloma Cancer Cells, Study Finds
TIMP-1 Biomarker Predicts Myeloma Progression And Survival
Beacon NewsFlashes – October 2, 2009
►
September
(19)
Taking Vitamin D And Calcium Supplements Together May Prevent Cancer
New Drug Enters Phase 2 Clinical Trial For Stem Cell Collection For Blood Cancer Patients
Second Dose Of Aloxi Further Reduces Chemotherapy-Induced Nausea In Cancer Patients
New Study Highlights Myeloma Treatment Infection Risks
Beacon NewsFlashes – September 23, 2009
Study On Myeloma Diagnosis Techniques Favors Newer Imaging Methods
Phase 3 Trial Indicates Denosumab Delays Skeletal Related Events In Cancer Patients
Study Shows Mozobil Induces Mobilization Of Stem Cells But Not Myeloma Tumor Cells
Study Supports Use Of Kyphoplasty For Multiple Myeloma Patients
Beacon NewsFlashes – September 16, 2009
Swine Flu Vaccinations Recommended For Multiple Myeloma Patients
Beacon NewsFlashes – September 12, 2009
Red Wine, Resveratrol, And Multiple Myeloma: The Evidence Is Promising, But Needs Further Study
Multiple Myeloma Conferences To Be Held In Hawaii, Arizona, Canada, And Greece
FDA To Review Velcade-Melphalan-Prednisone Regimen
Combination Actimid And Dexamethasone Regimen Is Promising For Relapsed And Refractory Myeloma Patients
Scientists Find A Protein That Causes Resistance To Velcade Treatment
Macrophages May Contribute To Survival Of Multiple Myeloma Cells
Beacon NewsFlashes – September 1, 2009
►
August
(17)
Personal Perspective: Engineer With Myeloma Finds Hope Through Cancer Support Group And Blogs
Beacon NewsFlashes – August 27, 2009
Pathologic Fractures In Bisphosphonate-Treated Patients Not Indicative Of Myeloma Progression
Personal Perspective: The Adventures Of Cancer Girl
Eradicating H. pylori Infection Not Linked To MGUS Regression
Beacon NewsFlashes – August 20, 2009
Phase 1 Clinical Trial Studies Velcade And Zolinza In Myeloma Patients
Kidney Failure In Multiple Myeloma Patients - Part 4: Hemodialysis
Beacon NewsFlashes - August 14, 2009
Skipped Bone Marrow Exams Give False Positives In Multiple Myeloma Clinical Trials
Multiple Myeloma Vaccine Shows Promise In Mice
High Incidence Of Multiple Myeloma In World Trade Center Responders
Research Shows Velcade’s Possible Mechanism of Action
Shortage of Clinical Trial Participants Hinders War On Cancer
Beacon NewsFlashes – August 6, 2009
Perifosine Advances To Phase 3 Multiple Myeloma Clinical Trial
Beacon NewsFlashes - August 3, 2009
►
July
(20)
Study Shows Toxicity Of Second Transplant For Myeloma Patients
Clinical Trials Start For A Pre-Transplant Treatment
Researchers Sequence Full Multiple Myeloma Tumor Genome
Beacon NewsFlashes – July 28, 2009
Multiple Myeloma Patients’ Relatives Are Twice As Likely To Have MGUS
Dr. Sagar Lonial Provides Insight Into High-Risk Myeloma
Vitamin D Deficiency May Cause Skeletal Complications In Multiple Myeloma Patients
Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma
Anti-DKK1 Antibody As New Treatment For Myeloma Bone Disease
Beacon BreakingNews - Clinical Trial Supports Revlimid As First-Line Therapy For Myeloma
Beacon NewsFlashes – July 21, 2009
Kidney Failure In Multiple Myeloma Patients – Part 3: Time and Care Commitments
Dental Exams Recommended Before Bisphosphonate Therapy
Kidney Failure In Multiple Myeloma Patients - Part 2: Treatment
Beacon NewsFlashes -- July 14, 2009
Quality Of Life Warrants More Consideration In Multiple Myeloma Treatment Recommendations
Study Examines Quality Of Life After Stem Cell Transplantation
Beacon NewsFlashes – July 8, 2009
Vegetarians Less Likely To Develop Multiple Myeloma
Revlimid As Initial Myeloma Therapy Inhibits Stem Cell Collection
►
June
(17)
Beacon NewsFlashes — June 30, 2009
Kidney Failure In Multiple Myeloma Patients - Part 1: Overview
XRCC5 Gene Variants Associated With Greater Blood Clot Risk During Thalidomide Treatment
Stem Cell Transplants May Improve Kidney Function of Myeloma Patients
Beacon NewsFlashes -- June 24, 2009
U.K. Finalizes Revlimid Therapy Guidelines
Canadian Authorities Confiscating Thalidomide At Border
Velcade Plus Dexamethasone Produces Robust, Yet Short-Lived, Response In Myeloma Patients
Beacon NewsFlashes - June 15, 2009
Revlimid Boosts Immune System Of Some Myeloma Patients
Beacon NewsFlashes - June 9, 2009
Study Shows Acute Kidney Failure Can Be Reversed By Velcade-Dexamethasone-Doxorubicin In Multiple Myeloma
Total Therapy Emerges As Prospect For Multiple Myeloma Cure
Myeloma Precursor MGUS Linked To Pesticide Use
Beacon NewsFlashes – June 3, 2009
Expert Panel Recommends European Approval Of Mozobil
Study Examines Romidepsin-Velcade Combination Treatment In Myeloma Patients (ASCO 2009)
►
May
(23)
ONJ As A Prognostic Factor In Myeloma Patients Treated With Zometa (ASCO 2009)
Beacon NewsFlashes - May 29, 2009
Nexavar Shows No Effect In Phase 2 Study (ASCO 2009)
MMRF Announces Research Collaboration With The Broad Institute
Clinical Trial Shows Ginger Reduces Nausea (ASCO 2009)
New Hemodialysis Procedure Improves Health Of Multiple Myeloma Patients
IGF-1: An Important Myeloma Growth Factor
Trial Investigates Effects Of Tanespimycin-Velcade Combination Treatment (ASCO 2009)
Autologous Stem Cell Transplant Therapy With Velcade-Revlimid Or Velcade-Thalomid in New Multiple Myeloma Patients (ASCO 2009)
Phase 3 Study Shows High Response Rates For Four-Drug Combination (ASCO 2009)
Beacon NewsFlashes - May 18, 2009
Formaldehyde Exposure Linked To Increased Risk Of Multiple Myeloma
ASCO 2009 - 45th Meeting Of The American Society Of Clinical Oncology Only Two Weeks Away
Myeloma Patients In Canada Smuggle Low-Priced Thalidomide
Beacon NewsFlashes – May 13, 2009
Mozobil With Neupogen Increases Stem Cell Harvest Efficiency
Iowa Firefighters And Police Officers To Benefit From Cancer Bill
Durie-Salmon Staging System And International Staging System Compared In Patients After ASCT
Socioeconomic Standing May Affect Survival For Swedish Myeloma Patients
Beacon NewsFlashes – May 9, 2009
Current Use Of Velcade In Newly Diagnosed Myeloma Patients
Study Projects Rising Cancer Rates In The United States
New Hampshire Legislature Approves Medical Marijuana Bill
►
April
(29)
Study Finds Lack Of Evidence For Link Between Firefighting And Cancer
Beacon NewsFlashes — April 28, 2009
The Access To Cancer Trials Act Of 2009 Brought Before Congress
Beacon NewsFlashes — April 27, 2009
NICE Recommends Revlimid For Multiple Myeloma Patients In U.K.
Melphalan-Prednisone Survival Rates Higher Than Thalidomide-Dexamethasone In Elderly
Study Measures Effects Of Novel Drugs On Myeloma Patients With Chromosomal Abnormalities
Beacon NewsFlashes – April 22, 2009
Long-Term Outcome Of Combination Auto/Allo Stem Cell Transplant Treatment Reported
Beacon NewsFlashes – April 20, 2009
Beacon NewsFlashes – April 17, 2009
New Revlimid Warning For Patients With Impaired Kidney Function
Gene Identification Could Lead To Better Treatment Options For Multiple Myeloma
High-Risk Myeloma Patients Show Overall Lower Progression-Free Survival With Revlimid-Dexamethosone Therapy
Thalidomide Plus Prednisone Shown To Improve Survival After ASCT
Beacon NewsFlashes – April 13, 2009
Beacon NewsFlashes – April 10, 2009
IMW 2009 - Physicians Debate "Cure Versus Control" Of Myeloma
IMW 2009 – Physicians Discuss Induction Therapy For Non-Transplant Candidates
IMW 2009 - Elotuzumab And Panobinostat Clinical Trials With Velcade
CMS Decides To Cover PET Scans For Myeloma Patients
Addition Of Salubrinal Could Dramatically Improve Velcade Response
Beacon NewsFlashes – April 7, 2009
Tools For Diagnosing Multiple Myeloma / Part 4: Specialized Studies
Growth In Off-Label Drug Use Slows
Blood Cancers Forum Focuses On Importance Of Clinical Trials
IMW 2009 – Physicians Discuss Upfront And Induction Therapy For Transplant Candidates
Beacon NewsFlashes – April 1, 2009
Medicare Expands Coverage Of Off-Label Uses Of Cancer Drugs – Part 2: Medicare-Approved Compendia
►
March
(31)
New Gene Implicated In Multiple Myeloma And Other Cancers
Kennedy Renews War On Cancer
The MMRF Marathon And Half Marathon Program Seeks Runners
Beacon NewsFlashes – March 29, 2008
Beacon NewsFlashes - March 27, 2009
Genetic Blood Tests Could Soon Identify Multiple Myeloma And Other Disorders
Beacon NewsFlashes – March 25, 2009
Tools For Diagnosing Multiple Myeloma / Part 3: Prognostic Evaluation
Beacon NewsFlashes – March 23, 2009
Beacon NewsFlashes – March 21, 2009
Beacon NewsFlashes – March 20, 2009
Scotland Expected To Improve Patient Access To New Cancer Therapies
Beacon NewsFlashes - March 16, 2009
IMW 2009 - Physicians Discuss New Drugs For Relapsed/Refractory Patients
Beacon NewsFlashes - March 14, 2009
Tools For Diagnosing Multiple Myeloma / Part 2: End-Organ Damage Evaluation
New Myeloma Drugs Target Different Mechanisms: Misfolded Proteins
Current Information On Response Criteria For Multiple Myeloma
IMW 2009 - Physicians Discuss Symptom Management Strategies
Beacon NewsFlashes - March 10, 2009
Managing The Side Effects Of Revlimid And Velcade
Beacon NewsFlashes – March 9, 2009
Current Information On Risk Stratification In Multiple Myeloma
New Myeloma Drugs Target Different Mechanisms: Signaling Pathways
Beacon NewsFlashes - March 6, 2009
IMW 2009 - Waldenstrom's Award Goes To IMF Co-Founder And Chairman
Blood Disorder MGUS Precedes Most Cases Of Multiple Myeloma
The MMRF Awards $1 Million For Promising Early-Stage Drug Development
Beacon NewsFlashes – March 2, 2009
IMW 2009 – Consensus On Risk Stratification In Multiple Myeloma
Beacon NewsFlashes - March 1, 2009
►
February
(32)
Current Information On Staging Multiple Myeloma
New Myeloma Drugs Target Different Mechanisms Of Action: Cell Surface Receptors
Canadian Survey Highlights Myeloma Awareness And Access To Treatment
Beacon NewsFlashes - February 24, 2009
IMW 2009 - Physicians Offer Standardized Guidelines For Diagnosing Suspected Multiple Myeloma
Radiation Not Linked To MGUS Progression To Multiple Myeloma
Beacon NewsFlashes - February 23, 2009
IMW 2009 - Doctors Clarify Standards For Clinical Trial Reporting
Physicians Perform First Bone Marrow Transplant At Public Hospital In West Bengal, India
Health Care-Associated MRSA In Decline
XII International Myeloma Workshop Begins Next Week
Clarifications And Updates In Diagnosis Criteria Of Multiple Myeloma
Tools For Diagnosing Multiple Myeloma / Part 1: Diagnostic Evaluation
Beacon NewsFlashes - February 18, 2009
Bill Helps Oregon Firefighters Get Cancer Coverage
Medicare Expands Coverage Of Off-Label Uses Of Cancer Drugs – Part 1
MMRF And LLS Grant $500,000 For Study Of The Multiple Myeloma Stem Cell
The American Society Of Clinical Oncology Provides A Financial Guide To Cancer Care
Long-Term Survival Estimates Increase For Young Multiple Myeloma Patients
Researchers Identify Novel Tumor Feeding Mechanism
Beacon NewsFlashes - February 11, 2009
Beacon NewsFlashes - February 11, 2009
Leukemia & Lymphoma Society And Women’s Running Magazine Join Forces To Launch New Women’s Half Marathon
Regulations And The Rising Cost Of Cancer Drugs
MMRF Is The Official Charity Of The Rite Aid Cleveland 5K
Beacon NewsFlashes - February 6, 2009
Green Tea Blocks Effectiveness Of Velcade Treatment
Beacon NewsFlashes - February 4, 2009
Study Finds No Link Between Hair Dyes And Myeloma
Beacon NewsFlashes – February 2, 2009
Deal Brings Revlimid To U.K. Myeloma Patients
Beacon NewsFlashes - February 1, 2009
►
January
(30)
Preventive Measures Can Reduce Osteonecrosis Of The Jaw In Patients Taking Zometa
Fruits And Vegetables Do Not Decrease Risk of Multiple Myeloma
Beacon NewsFlashes – January 28, 2008
FJC Awards $1 Million Grant To Institute For Myeloma And Bone Cancer Research
Blood Cancers The Subject Of Seminar At University Of Chicago Medical Center
Beacon NewsFlashes – January 26, 2009
Radiation Therapy, Vertebroplasty, And Kyphoplasty: Three Treatments For Myeloma Bone Disease
Scientists Develop Serum Immunoglobulin Free Light Chain Assay For Early Myeloma Diagnosis
Chemical Used In Rubber Synthesis Increases Risk Of Myeloma
New Drug for Preventing Nausea and Vomiting During Chemotherapy
Beacon NewsFlashes – January 21, 2009
MMRF Meeting Discusses Prognosis And Treatments For Myeloma Patients
Multiple Myeloma Treatment Approaches And Objectives
Phase 3 Zolinza-Velcade Trial Opening Soon
New Clinical Trials Combine Zolinza And Velcade For Multiple Myeloma Treatment
Beacon NewsFlashes - January 19, 2009
Thalomide Approved For First-Line Treatments In Scotland
Treatment In Elderly Multiple Myeloma Patients
Tandem Autologous Stem Cell Transplantation Compared To Single Autologous Stem Cell Transplantation
Managing Steroid-Related Side Effects In Myeloma Patients
MMRF Meeting Discusses Racial Disparities In Multiple Myeloma
Novel Therapies For Myeloma Bone Disease
Beacon NewsFlashes – January 13, 2009
Bisphosphonate Treatment For Myeloma Bone Disease
Beacon NewsFlashes – January 9, 2009
Phase 1 Clinical Trial Of CX-4945 Begins In Cancer Patients
U.K. To Expand Access To Drugs For Terminally Sick
Anti-Cancer Drug Zolinza Shows Potential In Myeloma
Beacon NewsFlashes – January 5, 2009
Osteoporosis Drug Increases Risk Of Esophageal Cancer And Jaw Disease
►
2008
(65)
►
December
(34)
Beacon NewsFlashes - December 30, 2008
Cancer Drugs To Cost More Under Medicare Plans
Leading Oncologists Present Clinical Research Advances in 2008
Clinical Trials Begin For New Form Of Radiotherapy
Skeletal Imaging For Bone Lesions In Multiple Myeloma Patients
ASH 2008 - New Induction Therapy for Elderly Patients
ASH 2008 - High Response Rate for Revlimid-Velcade-Dexamethasone Treatment in Phase 2 Studies
Diana Krall To Host Fundraiser Benefiting Blood Cancer Patients
FDA Approves Mozobil For Myeloma Patients Preparing For Stem Cell Transplants
Treatment In Young Multiple Myeloma Patients
ASH 2008 – Results Of Tandem Stem Cell Treatment For Newly Diagnosed Myeloma Patients
ASH 2008 - Ongoing Phase 2 Clinical Trials For Carfilzomib Show Promising Results
ASH 2008 - Carfilzomib, A Novel Drug Related To Velcade, Reduces Peripheral Neuropathy
ASH 2008 – Trial Results Compare Multiple Myeloma Transplantation Procedures
ASH 2008 – Venous Thrombotic Events In Newly Diagnosed Myeloma Patients Decrease Overall Survival
Beacon NewsFlashes - December 16, 2008
Impact of PET Scans Consistent Across All Types of Cancer
ASH 2008 – Perifosine Effective Against Multiple Myeloma In Combination With Dexamethasone-Revlimid And Dexamethasone-Velcade
Beacon NewsFlashes - December 12, 2008
ASH 2008 – Clinical Trial Update for Velcade-Thalidomide-Dexamethasone With Autologous Stem Cell Transplantation In Newly Diagnosed Myeloma Patients
Multiple Myeloma Research Consortium Announces Center Of The Year
ASH 2008 – Updated Velcade-Melphalan-Prednisone Trial Results For Newly Diagnosed Myeloma Patients
Deep Vein Thrombosis Risk Higher In Multiple Myeloma
ASH 2008 - VDD Initial Treatment More Effective Than TD Initial Treatment
ASH 2008 - Actimid-Dexamethasone Combination Highly Effective In Treating Relapsed And Refractory Multiple Myeloma
ASH 2008 - Scientists Reveal Promising Four-Drug Regimen For Newly-Diagnosed Myeloma Patients
Phase 3 Trials Of Hsp90 Inhibitors In Cancer Patients Underway
Outpatient Stem Cell Transplant For Multiple Myeloma
New Therapies Show Promise For Multiple Myeloma Treatment
Beacon NewsFlashes - December 5, 2008
Multiple Myeloma Survivors Honored At 2008 ASH Meeting
50th Annual Meeting Of The American Society Of Hematology Only Days Away
Beacon NewsFlashes – December 2, 2008
Physicians Discuss Past Progress And Future Goals In Treating Multiple Myeloma
►
November
(30)
Holiday Party In Las Vegas To Benefit The Leukemia & Lymphoma Society
Parade In New Zealand To Benefit Families Living With Multiple Myeloma
U.S. Cancer Incidence And Mortality Rates Fall For The First Time
Revlimid Combination Effective Against Relapsed And Refractory Myeloma
Beacon NewsFlashes - November 23, 2008
Increased Risk Of Blood Clotting Reported In Patients Treated With Avastin
IMF Continues Support Of Peter Boyle Memorial Fund
Long-Term Exposure To Benzene Appears To Increase Risk Of Multiple Myeloma
New Technique Shows Improved Detection Of Myeloma Tumor Cells After Treatment
IMF Announces New Global Research Partnership To Study Multiple Myeloma Biomarkers
Beacon NewsFlashes - November 17, 2008
Treatment With Folic Acid And B Vitamins Has Little Effect On Multiple Myeloma Risk Among Women
Beacon NewsFlashes - November 14, 2008
Link Between Gene Variation And Myeloma Survival
ImmunoCellular Therapeutics Presents Data Showing Immune Response On Cancer Stem Cells
Occupation And Chemical Exposure Linked To Multiple Myeloma
African-Americans Still At Higher Risk Of Developing Multiple Myeloma
Beacon NewsFlashes - November 11, 2008
CIGNA, Leukemia & Lymphoma Society Promote Financial Aid Program
Beacon NewsFlashes - November 7, 2008
International Myeloma Foundation Calls For Patient Access To Newest Myeloma Treatments
Beacon NewsFlashes – November 6, 2008
Antibody Treatment In Mice Shows Antitumor Activity
Prolexys Pharmaceuticals Raises $20 Million To Further Work On Anti-Tumor Molecule
Immune System Cells Show Promise As Multiple Myeloma Therapy
FDA Approves Cephalon's Treanda For Second Cancer Indication
MMRF Raises Over $1.5 Million In Annual Fall Gala
Incidence Of Multiple Myeloma In Women May Correlate With Height, Not Obesity
England And Wales May Halt Funding For Revlimid
Scientist Receives $720,000 Grant To Research New Multiple Myeloma Drug Targets
►
October
(1)
A New Beacon For The Multiple Myeloma Community
©2012
Light Knowledge Resources LLC
